[Blood cell concentration of XXXX in long-term therapy of inflammatory rheumatic diseases].

@entity1 @entity82 @entity5144 @entity1500 @entity1499 @entity309
To verify the possibility of a concomitant therapy control in 31 @entity1 (18 @entity5144 [ @entity5144 ], 13 @entity309 [ @entity309 ]) the blood cell concentration of @entity1499 ( @entity1500 ) was continuously measured over a period of 6 months. The determinations were carried out by using a RIA of the CIS Corp. At any time @entity1500 was determined laboratory and clinical examinations were done and the P-III-P serum-level was measured by using a RIA of the Behringwerke. The cellular @entity1500 showed to be statistically significantly elevated compared to baseline, whereas within ranges of total cumulative dosages only insignificant fluctuations could be noticed. Like in the treatment of Psoriasis a strict correlation between the weekly administered dose and the cellular @entity1500 could be established, the total cumulative dose, however, had no influence on the cellular @entity1500 -level. In the treatment of @entity309 slightly higher weekly dosages were necessary, which caused significantly higher cellular @entity1500 concentrations in @entity309 @entity1 . Some correlations between clinical as well as serological parameters of disease activity could be noticed, nevertheless they do not allow distinct interpretations. In both diseases a significant relationship between the cellular @entity1500 -level and the P-III-P serum-level could be realized. A storage of @entity1500 in blood cells, especially in erythrocytes, seems to be evident. To reach therapeutical benefit in @entity309 slightly higher mean dosages may be necessary. A therapy monitoring by the means of continuous determinations of cellular @entity1500 seems to be impossible. In contrast an approach to the early detection of liver @entity82 can be given by the correlation between cellular @entity1500 and the P-III-P serum levels.
